Printer Friendly

Browse Biological products topic

Product development subtopic

Articles

1-234 out of 234 article(s)
Title Author Type Date Words
I-MAB, MorphoSys announce FDA clearance of IND for MOR210/TJ210. Sep 17, 2020 195
Sutro Biopharma reports Phase 1 data of STRO-002 in ovarian cancer. Sep 9, 2020 240
Cellectar Biosciences reports data on CLR 131 Phase 2 CLOVER-1 study. Drug overview Sep 9, 2020 178
VelosBio Receives FDA Fast Track and Orphan Drug Designations for VLS-101 in Patients with Mantle Cell Lymphoma. Sep 2, 2020 333
BeiGene to develop, manufacture Singlomics anti-COVID-19 antibodies. Clinical report Aug 27, 2020 215
HiFiBiO Therapeutics Submits IND Application for Fully Human SARS-CoV-2 Neutralizing Antibody for the Treatment of COVID-19 Patients. Aug 26, 2020 332
Amplyx Pharmaceuticals doses first patient in MAU868 phase two clinical trial. Clinical report Aug 18, 2020 160
Amplyx Pharmaceuticals doses first patient in MAU868 phase two clinical trial. Clinical report Aug 18, 2020 156
Daiichi Sankyo Forges Clinical Trial Collaboration with AstraZeneca to Evaluate Patritumab Deruxtecan in Combination with TAGRISSO in EGFR-Mutated Non-Small Cell Lung Cancer. Aug 11, 2020 725
US announces clinical trial of antibody treatment for COVID-19. Aug 5, 2020 367
National Institutes of Health Selects Humanigen's Lenzilumab for its COVID-19 Big Effect Trial. Jul 29, 2020 316
Alector announces publication of preclinical, Phase 1 data on AL002. Jun 25, 2020 406
MacroGenics announces presentation of preclinical data at AACR meeting. Jun 22, 2020 435
Mersana Therapeutics presents preclinical data on XMT-1592. Jun 22, 2020 283
SpringsWorks Therapeutics: Dosing begins in Phase 1b study of nirogacestat. Jun 22, 2020 159
Navidea announces full enrollment in Phase 2b trial of Tc99m Tilmanocept. Jun 15, 2020 264
AbbVie, Genmab announce oncology collaboration to develop antibody products. Jun 10, 2020 446
Eli Lilly begins Phase 1 study for second potential COVID-19 antibody treatment. Jun 8, 2020 199
China begins clinical trials of neutralising antibody Covid-19 treatment. Jun 7, 2020 404
Alligator Bioscience reveals status of ongoing ATOR-1015 Phase I clinical trial. Apr 27, 2020 224
Alligator Bioscience reveals status of ongoing ATOR-1015 Phase I clinical trial. Apr 27, 2020 228
Innovent Biologics, Eli Lilly announce NMPA of China accepts NDA for Tyvyt. Apr 23, 2020 240
Humanigen moves a step closer to a Phase III trial to tackle leading cause of death in coronavirus. Mar 28, 2020 364
Harbour BioMed Receives US FDA IND Approval for Phase 2 Clinical Trial and Orphan Drug. Mar 4, 2020 421
HUYA Bioscience International concludes the Phase 1 Trial of HBI-3000 for acute atrial fibrillation treatment. Mar 2, 2020 238
HUYA Bioscience International concludes the Phase 1 Trial of HBI-3000 for acute atrial fibrillation treatment. Mar 2, 2020 234
Daiichi Sankyo and AstraZeneca report positives topline result from phase 2 DESTINY trial of DS-8201 for metastatic gastric cancer. Jan 27, 2020 344
Daiichi Sankyo and AstraZeneca report positives topline result from phase 2 DESTINY trial of DS-8201 for metastatic gastric cancer. Jan 27, 2020 340
TOP NEWS: Astra Ends Epanova Trial; Lynparza Gets US Priority Review. Jan 13, 2020 372
WuXi Biologics announces FDA clearance of IND application for next generation antibody ONC-392. Jan 2, 2020 161
WuXi Biologics announces FDA clearance of IND application for next generation antibody ONC-392. Jan 2, 2020 165
AstraZeneca and Daiichi Sankyo reveal positive data from trastuzumab deruxtecan Phase II single-arm DESTINY-Breast01 trial. Dec 13, 2019 234
AstraZeneca and Daiichi Sankyo reveal positive data from trastuzumab deruxtecan Phase II single-arm DESTINY-Breast01 trial. Dec 13, 2019 238
Seattle Genetics, Astellas Forge Clinical Trial Collaboration with US Merck to Evaluate Enfortumab. Dec 3, 2019 456
Compugen receives FDA clearance of IND application for COM902 in patients with advanced malignancies. Nov 5, 2019 234
Compugen receives FDA clearance of IND application for COM902 in patients with advanced malignancies. Nov 5, 2019 230
Sutro Biopharma presents data from Phase I study of STRO-002. Oct 29, 2019 261
Navidea says NAV3-31 Phase 2B study data supports hypotheses. Oct 29, 2019 397
Catalyst says two subjects exceed efficacy endpoint in DalcA Phase 2b study. Oct 3, 2019 220
ImmunoGen Presents Initial Data from Phase 1b FORWARD II Triplet Cohort Evaluating Mirvetuximab Soravtansine in Combination with Carboplatin and Avastin at ESMO. Oct 2, 2019 385
RegeneRx: Phase 3 ARISE-3 trial 'progressing smoothly' according to plan. Sep 30, 2019 333
ImmunoGen to Present Full Data from Phase 3 FORWARD I Study of Mirvetuximab Soravtansine and Initial Data from Phase 1b FORWARD II Triplet Cohort at ESMO. Sep 19, 2019 234
AstraZeneca achieves primary endpoint in anifrolumab phase III Tulip two trial. Sep 2, 2019 184
AstraZeneca achieves primary endpoint in anifrolumab phase III Tulip two trial. Sep 2, 2019 180
Breakthrough trial shows Ebola is now curable. Aug 15, 2019 175
Scientists hail promise of first effective Ebola treatments in Congo trial. Aug 13, 2019 472
Scientists hail promise of first effective Ebola treatments in Congo trial. Aug 12, 2019 549
RegeneRx announces enrollment of first patient in RGN-137 trial. Aug 5, 2019 262
Aptevo Therapeutics completes dosing in SAD Phase 1 study of APVO210. Jul 25, 2019 114
Mereo BioPharma, FDA discuss design outline for Phase 2 trial of navicixizumab. Jul 15, 2019 320
Alder presents new data from PROMISE-1, PROMISE-2 Phase 3 trial analyses. Jul 11, 2019 344
Catalyst Biosciences Phase 2 trial of MarzAA met primary endpoint. Jul 8, 2019 126
Bioinvent granted authorisation by US FDA to proceed with Phase I/IIa clinical trial of an immune-modulatory anti-FcI[superscript three]RllB antibody. Jul 2, 2019 219
Bioinvent granted authorisation by US FDA to proceed with Phase I/IIa clinical trial of an immune-modulatory anti-FcI[superscript three]RllB antibody. Jul 2, 2019 215
Horizon Therapeutics Initiates MIRROR Randomised Controlled Trial Evaluating Krystexxa in Combination with Methotrexate to Increase Response Rates and Duration of Therapy. Jun 26, 2019 223
Horizon Therapeutics starts clinical trial of KRYSTEXXA in combination with methotrexate. Jun 24, 2019 164
Horizon Therapeutics starts clinical trial of KRYSTEXXA in combination with methotrexate. Jun 24, 2019 160
Alligator Bioscience applies for phase one clinical trial authorisation for ATOR-1017. Jun 19, 2019 159
Alligator Bioscience applies for phase one clinical trial authorisation for ATOR-1017. Jun 19, 2019 155
Corvidia Therapeutics starts patient screening for Ziltivekimab Phase 2b study. Clinical report Jun 17, 2019 193
Corvidia Therapeutics starts patient screening for Ziltivekimab Phase 2b study. Clinical report Jun 17, 2019 189
TG Therapeutics presents preclinical data for TG-1801 at EHA Congress. Jun 17, 2019 186
Sutro Biopharma announces interim Phase 1 safety data for STRO-001. Jun 16, 2019 105
Bristol-Myers announces data from Phase 4 Orencia study at EULAR. Jun 13, 2019 316
Selecta Biosciences presents data from Phase 2 trial of Sel-212. Jun 12, 2019 269
Avacta Selects Candidate For First Human Trials Of Affimer Platform. Jun 10, 2019 377
BioInvent submits IND with US FDA for Phase I/IIa trial of anti-FcI[superscript three]RIIB antibody. Jun 3, 2019 252
BioInvent submits IND with US FDA for Phase I/IIa trial of anti-FcI[superscript three]RIIB antibody. Jun 3, 2019 248
AstraZeneca - Pivotal Phase II DESTINY-Breast01 trial met primary endpoint, supporting global regulatory submission plan to start in H2 2019 - 8/5/2019. May 21, 2019 408
AbbVie withdraws phase three trial of depatuxizumab mafodotin. May 21, 2019 192
AbbVie withdraws phase three trial of depatuxizumab mafodotin. May 21, 2019 188
Alligator Bioscience announces that data of ADC-1013 from phase I clinical trial will be presented at ASCO. May 16, 2019 303
Alligator Bioscience announces that data of ADC-1013 from phase I clinical trial will be presented at ASCO. May 16, 2019 299
AstraZeneca - Pivotal Phase II DESTINY-Breast01 trial met primary endpoint, supporting global regulatory submission plan to start in H2 2019 -- 8/5/2019. May 15, 2019 408
RegeneRx enrolls first patient in RegeneRx JV phase 3 dry eye trial. May 13, 2019 191
AstraZeneca says Phase 2 DESTINY-Breast01 trial met primary endpoint. May 8, 2019 135
Forbius doses first patient with AVID100 in Phase 2a triple negative breast cancer clinical trial. Apr 24, 2019 232
Forbius doses first patient with AVID100 in Phase 2a triple negative breast cancer clinical trial. Apr 24, 2019 228
First Patient Dosed in Phase 2a EGFR-Overexpressing Triple Negative Breast Cancer Trial of AVID100, a Novel, Tumor-Specific Anti-EGFR ADC. Apr 24, 2019 387
Seattle Genetics completes enrollment in pivotal innovaTV 204 phase 2 trial. Mar 29, 2019 117
Alligator Bioscience to present new preclinical data for the drug candidate ATOR-1017 at the 4th Annual Immuno-oncology Summit Europe, London. Mar 19, 2019 236
Innovent doses first malignant tumour patient in Phase I clinical trial of anti-CD47 monoclonal antibody in the US. Mar 19, 2019 249
Innovent doses first malignant tumour patient in Phase I clinical trial of anti-CD47 monoclonal antibody in the US. Mar 19, 2019 245
Magenta Therapeutics presents preclinical data on targeted conditioning programs. Feb 25, 2019 746
Tanabe Research Laboratories USA Inc files first IND application with the US FDA for phase I trial of TR1801-ADC in cMet positive solid tumours patients. Feb 15, 2019 228
Tanabe Research Laboratories USA Inc files first IND application with the US FDA for phase I trial of TR1801-ADC in cMet positive solid tumours patients. Feb 15, 2019 224
Alligator Bioscience announces publication of clinical phase I data for ADC-1013 in the International Journal of Cancer. Jan 30, 2019 245
Alligator Bioscience announces publication of clinical phase I data for ADC-1013 in the International Journal of Cancer. Jan 30, 2019 246
Eisai in collaboration with University College London to start Phase I clinical trials of Alzheimer's drug E2814. Dec 11, 2018 197
Eisai in collaboration with University College London to start Phase I clinical trials of Alzheimer's drug E2814. Dec 11, 2018 193
Thermo Fisher Scientific opens Maryland business centre and biorepository. Nov 1, 2018 194
Thermo Fisher Scientific opens Maryland business centre and biorepository. Nov 1, 2018 190
Adagene treats first patient with ADG-106 in the US & announces ADG-106 IND filing in China. Nov 1, 2018 185
Adagene treats first patient with ADG-106 in the US & announces ADG-106 IND filing in China. Nov 1, 2018 181
Bristol-Myers Squibb doses first patient in clinical trial of BMS-986179. Oct 29, 2018 195
Bristol-Myers Squibb doses first patient in clinical trial of BMS-986179. Oct 29, 2018 191
Bristol-Myers doses first subject in Phase 1 trial using Halozyme's Enhanze. Oct 25, 2018 153
Selecta Biosciences reports patient death in Phase 1 SEL-403 trial. Oct 18, 2018 401
Innovent passes US FDA approval to initiate clinical trials of Anti-CD47 Monoclonal Antibody IBI-188. Oct 1, 2018 237
Innovent passes US FDA approval to initiate clinical trials of Anti-CD47 Monoclonal Antibody IBI-188. Oct 1, 2018 233
AstraZeneca updates on TULIP 1 Phase III trial for anifrolumab. Aug 31, 2018 251
AstraZeneca updates on TULIP 1 Phase III trial for anifrolumab. Aug 31, 2018 247
Agenus receives second milestone payment from Merck. Aug 15, 2018 114
FDA Accepts Ocular Therapeutix' NDA Resubmission for Dextenza. Jul 25, 2018 272
Seattle Genetics announces first patient dosed in phase 2 innovaTV 207 trial. Jul 12, 2018 241
Seattle Genetics, Astellas Pharma report enrollment completion in Phase 2 trial. Jul 9, 2018 212
Seattle Genetics, Astellas complete enrollment in enfortumab vedotin trial. Jul 9, 2018 178
Ocular Therapeutix Resubmits Dexenza NDA to US FDA. Jul 5, 2018 197
Compugen announces FDA clearance of IND application for COM701. Jul 2, 2018 292
Alder says PROMISE 1 trial data demonstrates long-term efficacy of Eptinezumab. Jun 29, 2018 244
Seattle Genetics Begins Phase 2 Trial of Tisotumab Vedotin in Cervical Cancer Patients. Jun 19, 2018 273
Seattle Genetics announces dosing in Phase 2 innovaTV 204 clinical trial. Jun 13, 2018 209
iBio announces joint product development in Brazil. Jun 5, 2018 125
Seattle Genetics, Astellas present updated phase 1 data of enfortumab vedotin. Jun 3, 2018 191
Daiichi Sankyo Initiates Phase 2 Study of lung cancer drug DS-8201. Jun 1, 2018 250
Daiichi Sankyo Initiates Phase 2 Study of lung cancer drug DS-8201. Jun 1, 2018 246
Scholar Rock completes dosing of first cohort in Phase 1 trial of SRK-015. May 31, 2018 160
Ocular Therapeutix Doses First Patient in Phase 1 Trial of Travoprost Intracameral Implant for Treatment of Glaucoma, Ocular Hypertension. May 7, 2018 268
Siamab Therapeutics Publishes Preclinical Data on ADC for Treatment of Solid Tumors. May 3, 2018 271
Sutro Doses First Patients in Clinical Trial of STRO-001 for Treatment of Lymphoma and Multiple Myeloma. Apr 30, 2018 302
ADC Therapeutics withdraws phase I clinical trial to evaluate ADCT-502. Apr 27, 2018 221
ADC Therapeutics withdraws phase I clinical trial to evaluate ADCT-502. Apr 27, 2018 217
Sutro Doses First Patients in Clinical Trial of STRO-001 for Treatment of Lymphoma and Multiple Myeloma. Apr 27, 2018 302
Selecta Biosciences reports 'positive' data from Phase 2 trial of SEL-212. Apr 10, 2018 322
Keryx announces publication of data from phase 3 trial of Auryxia. Clinical report Apr 4, 2018 212
Zealand Pharma reports meeting of primary objective of first phase 3 trial with dasiglucagon. Mar 21, 2018 258
Zealand Pharma reports meeting of primary objective of first phase 3 trial with dasiglucagon. Mar 21, 2018 254
Tethis Develops Bio-Mased Material to Replace Diaper Polymers. Brief article Mar 1, 2018 172
Actinium reports trial to study Actimab-A, CLAG-M combination in AML. Feb 6, 2018 277
MiMedx Enrolls First Patients in Phase 3 Trial Of AmnioFix Injectable in Patients with Recalcitrant Plantar Fasciitis Pain. Jan 19, 2018 288
A Multicentric, Open-Label, Randomized, Comparative Clinical Trial of Two Different Doses of Expanded hBM-MSCs Plus Biomaterial versus Iliac Crest Autograft, for Bone Healing in Nonunions after Long Bone Fractures: Study Protocol. Gomez-Barrena, Enrique; Padilla-Eguiluz, Norma G.; Avendano-Sola, Cristina; Payares-Herrera, Concepc Jan 1, 2018 8675
Merck fails to meet primary endpoint in Keytruda phase three gastric cancer trial. Dec 19, 2017 181
Merck fails to meet primary endpoint in Keytruda phase three gastric cancer trial. Dec 19, 2017 177
Visterra Receives FDA Fast Track Designation for VIS410 for Treatment of Hospitalized Influenza A Patients. Nov 2, 2017 322
Preclinical Data Demonstrate Safety of Siamab Therapeutics' Anti-STn Monoclonal Antibodies in Multiple Animal Models. Oct 31, 2017 320
New trial of immuno-oncology treatment for advanced tumours set to begin. Aug 9, 2017 213
New trial of immuno-oncology treatment for advanced tumours set to begin. Aug 9, 2017 209
AstraZeneca's Imfinzi in combination with tremelimumab fails phase three lung cancer trial. Jul 28, 2017 150
AstraZeneca's Imfinzi in combination with tremelimumab fails phase three lung cancer trial. Jul 28, 2017 146
Teleflex Starts Phase I Clinical Study of RePlas Freeze-Dried Plasma. May 16, 2017 469
A Review on: Phase '0' Clinical Trials or Exploratory Investigational New Drug/Klinik Faz '0' Testleri ya da Yeni Ilac Kesif Arastirmalari Uzerine Bir Derleme. Gawai, Ashish A.; Gadekar, Faisal Shaikh, Mangesh; Deokar, Nitin; Kolhe, Shivanand; Biyani, K.R. Report Apr 1, 2017 3621
UK's Medicines Healthcare Products Regulatory Agency Approves InVivo Therapeutics' Clinical Trial Application. Mar 16, 2017 325
Siamab Therapeutics Publishes New Preclinical Data. Mar 10, 2017 548
Janssen psoriasis drug successful in phase III trials. Mar 6, 2017 248
Janssen psoriasis drug successful in phase III trials. Mar 6, 2017 244
Otonomy enrols first patients in phase two clinical trial of OTO-104. Jan 20, 2017 193
Otonomy enrols first patients in phase two clinical trial of OTO-104. Jan 20, 2017 189
Seattle Genetics enrols first patient in multicentre phase 1 clinical trial of SGN-CD352A. Jan 9, 2017 174
Seattle Genetics enrols first patient in multicentre phase 1 clinical trial of SGN-CD352A. Jan 9, 2017 170
RegeneRx admits first patients in Phase 3 US dry eye clinical trial with RGN-259. Nov 10, 2016 303
RegeneRx admits first patients in Phase 3 US dry eye clinical trial with RGN-259. Nov 10, 2016 299
BIOCAD Biotechnology starts phase two clinical trials of BCD-085 for psoriasis. Oct 14, 2016 119
BIOCAD Biotechnology starts phase two clinical trials of BCD-085 for psoriasis. Oct 14, 2016 115
Alzheimer's drug trial raises hope; HEALTH. Sep 1, 2016 139
Adcetris meets primary endpoint in phase three clinical trial. Aug 3, 2016 209
Adcetris meets primary endpoint in phase three clinical trial. Aug 3, 2016 205
MabVax Therapeutics Starts Patient Enrollment in Phase I Trial of Diagnostic Imaging Product for Pancreatic Cancer. Jul 20, 2016 484
BioMarin Pharmaceutical enrols for Phase 1/2 trial of BMN 250. Apr 25, 2016 270
BioMarin Pharmaceutical enrols for Phase 1/2 trial of BMN 250. Apr 25, 2016 266
Otonomy commences Otiprio phase two clinical trial. Mar 7, 2016 208
Otonomy commences Otiprio phase two clinical trial. Mar 7, 2016 204
Seattle Genetics commences phase one clinical trial of B-cell non-Hodgkin lymphoma treatment. Feb 29, 2016 156
Seattle Genetics commences phase one clinical trial of B-cell non-Hodgkin lymphoma treatment. Feb 29, 2016 152
RegeneRx concludes patient enrollment in Phase 2b/3 US dry eye trial of RGN-259. Feb 1, 2016 231
RegeneRx concludes patient enrollment in Phase 2b/3 US dry eye trial of RGN-259. Feb 1, 2016 227
Enzyme Chemistry Reagents Diagnostic Tests - Medical Devices Pipeline Assessment, 2015. Jan 20, 2016 376
PARADIGM'S ZILOSUL APPROVED FOR CLINICAL TRIAL. Jan 1, 2016 759
Arsanis initiates first cohort in Phase one clinical trial of ASN100. Nov 25, 2015 127
Arsanis initiates first cohort in Phase one clinical trial of ASN100. Nov 25, 2015 123
"Dental Biomaterials - Pipeline Review, 2015" Published. Nov 9, 2015 405
Heraeus Medical and OrthoCyte partner to create bone-grafting therapies. Nov 1, 2015 545
RegeneRx announces USD500,000 milestone payment for treating first patient in US Phase 2b/3 dry eye trial. Oct 1, 2015 247
RegeneRx announces USD500,000 milestone payment for treating first patient in US Phase 2b/3 dry eye trial. Oct 1, 2015 243
RegeneRx treats first patient with RGN-259 in Phase 3 US Neurotrophic Keratopathy (NK) clinical trial; Data expected in early 2016. Sep 22, 2015 344
RegeneRx treats first patient with RGN-259 in Phase 3 US Neurotrophic Keratopathy (NK) clinical trial; Data expected in early 2016. Sep 22, 2015 340
RegeneRx admits first patients in Phase 2b/3 US dry eye clinical trial with RGN-259, with expected data in early 2016. Sep 17, 2015 270
RegeneRx admits first patients in Phase 2b/3 US dry eye clinical trial with RGN-259, with expected data in early 2016. Sep 17, 2015 266
Aridis' AR-301 product candidate granted fast track designation by US FDA. Sep 14, 2015 207
Aridis' AR-301 product candidate granted fast track designation by US FDA. Sep 14, 2015 203
BioClin Therapeutics starts Phase II clinical study of B-701. Aug 12, 2015 156
BioClin Therapeutics starts Phase II clinical study of B-701. Aug 12, 2015 152
Korea approves phase 2b/3 clinical trial in patients with Dry Eye syndrome. Aug 3, 2015 286
Belgian UCB says epratuzumab fails Phase III lupus trials. Jul 29, 2015 168
Korea approves phase 2b/3 clinical trial in patients with dry eye syndrome. Jul 27, 2015 287
Korea approves phase 2b/3 trial in patients with dry eye syndrome. Jul 27, 2015 287
RegeneRx to start Phase 2b/3 clinical trial of GBT-201/RGN-259 in patients with dry eye syndrome in Korea. Jul 20, 2015 237
RegeneRx to start Phase 2b/3 clinical trial of GBT-201/RGN-259 in patients with dry eye syndrome in Korea. Jul 20, 2015 233
AbGenomics starts Phase-Ib/IIa clinical trial of neihulizumab. May 20, 2015 121
AbGenomics starts Phase-Ib/IIa clinical trial of neihulizumab. May 20, 2015 117
WuXi PharmaTech's IND application for novel anti-IL6 monoclonal antibody for rheumatoid arthritis accepted for review by CFDA. Mar 27, 2015 245
WuXi PharmaTech's IND application for novel anti-IL6 monoclonal antibody for rheumatoid arthritis accepted for review by CFDA. Mar 27, 2015 241
RegeneRx & G-treeBNT partnership to develop RGN-259 in the US for ophthalmic indications. Jan 29, 2015 227
RegeneRx & G-treeBNT partnership to develop RGN-259 in the US for ophthalmic indications. Jan 29, 2015 223
OncoSynergy' OS2966 receives orphan drug designation from FDA's Office of Orphan Products Development. Jan 23, 2015 146
OncoSynergy' OS2966 receives orphan drug designation from FDA's Office of Orphan Products Development. Jan 23, 2015 142
BioInvent's Bi-1206 antibody to enter Collaborative Phase L/Ll Trial for CLL and NHL patients. Jan 20, 2015 437
BioInvent's Bi-1206 antibody to enter Collaborative Phase L/Ll Trial for CLL and NHL patients. Jan 20, 2015 433
G-treeBNT files IND for a Phase IIB/III clinical trial with RGN-259. Dec 30, 2014 195
G-treeBNT files IND for a Phase IIB/III clinical trial with RGN-259. Dec 30, 2014 191
Anthera & Patheon signs manufacturing agreement for Liprotamase Phase III Registration Trial. Nov 21, 2014 254
Anthera & Patheon signs manufacturing agreement for Liprotamase Phase III Registration Trial. Nov 21, 2014 250
MorphoSys receives fast track designation for MOR208 from US Food and Drug Administration. Nov 11, 2014 187
Sutro Biopharma, Celgene join forces to discover, develop antibodies, ADCs. Oct 23, 2014 364
RegeneRx to begin Phase 3 study of RGN-259 eye drops in neurotrophic keratopathy patients. Oct 21, 2014 220
RegeneRx to begin Phase 3 study of RGN-259 eye drops in neurotrophic keratopathy patients. Oct 21, 2014 216
Sutro Biopharma, Merck KGaA to jointly develop antibody drug conjugates. Sep 17, 2014 258
Develop restructured beef products using microbial transglutaminase, almonds as functional ingredients. Sep 1, 2014 371
OncoSynergy receives orphan drug designation for OS2966 from FDA Office of Orphan Products Development. Aug 14, 2014 145
OncoSynergy receives orphan drug designation for OS2966 from FDA Office of Orphan Products Development. Aug 14, 2014 141
Merck Serono, Mersana join forces to develop novel antibody-drug conjugates. Jun 24, 2014 259
Xencor receives milestone payment from Merck for initiation of phase 1 clinical trial. Apr 14, 2014 271
Xencor receives milestone payment from Merck for initiation of phase 1 clinical trial. Apr 14, 2014 267
Actinium Pharmaceuticals' Actimab-A drug candidate enters ongoing Phase 1/2 trial for newly diagnosed AML patients. Mar 25, 2014 189
Actinium Pharmaceuticals' Actimab-A drug candidate enters ongoing Phase 1/2 trial for newly diagnosed AML patients. Mar 25, 2014 185
BioMarin Pharmaceutical Inc treats first child with BMN 111 in Phase 2 trial of achondroplasia. Jan 15, 2014 186
BioMarin Pharmaceutical Inc treats first child with BMN 111 in Phase 2 trial of achondroplasia. Jan 15, 2014 182
SQI Diagnostics to develop 6-plex anti-drug antibody assay for US company. Dec 20, 2013 151
KaloBios' KB001-A granted Orphan drug Designation by US FDA. Oct 31, 2013 263
KaloBios' KB001-A granted Orphan drug Designation by US FDA. Oct 31, 2013 259
BioMarin Pharmaceutical Inc enrols first breast cancer patient in Phase 3 trial of BMN 673. Oct 31, 2013 199
BioMarin Pharmaceutical Inc enrols first breast cancer patient in Phase 3 trial of BMN 673. Oct 31, 2013 195
Bayer gets global rights of Seattle Genetics' ADC technique to develop antibody-drug conjugates. Jun 26, 2013 220
Catalent, Nascent to develop antibodies. May 1, 2012 224
KYTHERA Biopharmaceuticals commences ATX-101 Phase III trials. Mar 5, 2012 113
IMMUNE Granted US$1 Million (NIS 3.8M) by Israel. Mar 1, 2012 507
SK Biopharmaceuticals begins Phase 2 trial in the US. Feb 22, 2012 168
Global trials and the cold chain: strategies for ensuring the integrity and compliance of biomaterials. Hager, Russ Sep 1, 2011 1528
Emergent starts Phase I trial of antibody to treat inhalational anthrax. Sep 9, 2010 178
Oxigene announces positve preclinical data for AML drug. Dec 9, 2009 197
Oxigene announces good preclinical data for AML drug candidate. Dec 8, 2009 197
Panacea announces selection of PAN-622 - a fully human sequence monoclonal antibody against HAAH - as its lead cancer therapeutic product. Nov 1, 2007 793
Pieris progresses development of its proprietary biotherapeutics platform. Jun 1, 2007 534
Novel enzyme infusion technique uses positive pressure. Nov 1, 2005 315
Northwestern obtains United States patent. Brief Article Apr 1, 2005 133

Terms of use | Privacy policy | Copyright © 2020 Farlex, Inc. | Feedback | For webmasters